Calcineurin inhibitor-free immunosuppression in renal transplantation

Detalhes bibliográficos
Autor(a) principal: Parada, B
Data de Publicação: 2005
Outros Autores: Mota, A, Nunes, P, Macário, F, Pratas, J, Bastos, C, Figueiredo, A
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.4/1055
Resumo: PURPOSE: To describe our initial results using a calcineurin inhibitor-free immunosuppression protocol in renal transplants. PATIENTS AND METHODS: Between October 2001 and June 2003, 56 recipients of a renal allografts were started on an immunosuppression protocol without calcineurin inhibitors, consisting of basiliximab, sirolimus, mycophenolate mofetil, and steroids. We analyzed patient and graft survival, acute rejection episodes, and renal function. RESULTS: The mean follow-up was 19.6 months. Actuarial patient survival at 1 and 2 years was 98.1% and 95.3%, respectively. Actuarial graft survival at 1 and 2 years was 92.9% and 87.6%, respectively. Acute rejection occurred in 27.8% of the patients, usually Banff 1 (73.3%). There was stable renal function with mean serum creatinine of 1.3, 1.4, 1.3, and 1.3 mg/dL at 1, 6, 12, and 24 months after transplant. CONCLUSIONS: The use of immunosuppression free of calcineurin inhibitors is effective and safe. Further follow-up is needed to evaluate the impact on long-term results.
id RCAP_bad0618155e989164d5ab19c3ba3b11a
oai_identifier_str oai:rihuc.huc.min-saude.pt:10400.4/1055
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Calcineurin inhibitor-free immunosuppression in renal transplantationInsuficiência Renal CrónicaTransplantação de RimCalcineurinaImunossupressoresPURPOSE: To describe our initial results using a calcineurin inhibitor-free immunosuppression protocol in renal transplants. PATIENTS AND METHODS: Between October 2001 and June 2003, 56 recipients of a renal allografts were started on an immunosuppression protocol without calcineurin inhibitors, consisting of basiliximab, sirolimus, mycophenolate mofetil, and steroids. We analyzed patient and graft survival, acute rejection episodes, and renal function. RESULTS: The mean follow-up was 19.6 months. Actuarial patient survival at 1 and 2 years was 98.1% and 95.3%, respectively. Actuarial graft survival at 1 and 2 years was 92.9% and 87.6%, respectively. Acute rejection occurred in 27.8% of the patients, usually Banff 1 (73.3%). There was stable renal function with mean serum creatinine of 1.3, 1.4, 1.3, and 1.3 mg/dL at 1, 6, 12, and 24 months after transplant. CONCLUSIONS: The use of immunosuppression free of calcineurin inhibitors is effective and safe. Further follow-up is needed to evaluate the impact on long-term results.ElsevierRIHUCParada, BMota, ANunes, PMacário, FPratas, JBastos, CFigueiredo, A2011-09-07T11:25:19Z20052005-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/1055engTransplant Proc. 2005 Jul-Aug;37(6):2759-61.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-11T14:22:15Zoai:rihuc.huc.min-saude.pt:10400.4/1055Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:03:37.214281Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Calcineurin inhibitor-free immunosuppression in renal transplantation
title Calcineurin inhibitor-free immunosuppression in renal transplantation
spellingShingle Calcineurin inhibitor-free immunosuppression in renal transplantation
Parada, B
Insuficiência Renal Crónica
Transplantação de Rim
Calcineurina
Imunossupressores
title_short Calcineurin inhibitor-free immunosuppression in renal transplantation
title_full Calcineurin inhibitor-free immunosuppression in renal transplantation
title_fullStr Calcineurin inhibitor-free immunosuppression in renal transplantation
title_full_unstemmed Calcineurin inhibitor-free immunosuppression in renal transplantation
title_sort Calcineurin inhibitor-free immunosuppression in renal transplantation
author Parada, B
author_facet Parada, B
Mota, A
Nunes, P
Macário, F
Pratas, J
Bastos, C
Figueiredo, A
author_role author
author2 Mota, A
Nunes, P
Macário, F
Pratas, J
Bastos, C
Figueiredo, A
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv RIHUC
dc.contributor.author.fl_str_mv Parada, B
Mota, A
Nunes, P
Macário, F
Pratas, J
Bastos, C
Figueiredo, A
dc.subject.por.fl_str_mv Insuficiência Renal Crónica
Transplantação de Rim
Calcineurina
Imunossupressores
topic Insuficiência Renal Crónica
Transplantação de Rim
Calcineurina
Imunossupressores
description PURPOSE: To describe our initial results using a calcineurin inhibitor-free immunosuppression protocol in renal transplants. PATIENTS AND METHODS: Between October 2001 and June 2003, 56 recipients of a renal allografts were started on an immunosuppression protocol without calcineurin inhibitors, consisting of basiliximab, sirolimus, mycophenolate mofetil, and steroids. We analyzed patient and graft survival, acute rejection episodes, and renal function. RESULTS: The mean follow-up was 19.6 months. Actuarial patient survival at 1 and 2 years was 98.1% and 95.3%, respectively. Actuarial graft survival at 1 and 2 years was 92.9% and 87.6%, respectively. Acute rejection occurred in 27.8% of the patients, usually Banff 1 (73.3%). There was stable renal function with mean serum creatinine of 1.3, 1.4, 1.3, and 1.3 mg/dL at 1, 6, 12, and 24 months after transplant. CONCLUSIONS: The use of immunosuppression free of calcineurin inhibitors is effective and safe. Further follow-up is needed to evaluate the impact on long-term results.
publishDate 2005
dc.date.none.fl_str_mv 2005
2005-01-01T00:00:00Z
2011-09-07T11:25:19Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.4/1055
url http://hdl.handle.net/10400.4/1055
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Transplant Proc. 2005 Jul-Aug;37(6):2759-61.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131699201703936